Teladoc Health (NYSE:TDOC) Given New $20.00 Price Target at Barclays

Teladoc Health (NYSE:TDOC) had its target price reduced by Barclays from $25.00 to $20.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the health services provider’s stock. Barclays‘s target price would indicate a potential upside of 51.17% from the company’s previous close.

Several other equities analysts also recently weighed in on TDOC. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research note on Friday. Canaccord Genuity Group reduced their target price on shares of Teladoc Health from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler dropped their price target on shares of Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. SVB Leerink assumed coverage on Teladoc Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $17.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on Teladoc Health in a report on Thursday, February 29th. They set an “overweight” rating and a $22.00 price target on the stock. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and an average price target of $21.62.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded down $0.10 during trading on Friday, hitting $13.23. 3,465,501 shares of the stock traded hands, compared to its average volume of 4,744,668. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66. The company has a fifty day moving average price of $15.17 and a two-hundred day moving average price of $17.80. Teladoc Health has a 52-week low of $12.65 and a 52-week high of $30.41. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -9.97 and a beta of 0.94.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) earnings per share. As a group, equities analysts predict that Teladoc Health will post -1.07 EPS for the current year.

Insider Activity at Teladoc Health

In related news, CMO Stephany Verstraete sold 7,945 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $115,361.40. Following the transaction, the chief marketing officer now owns 56,486 shares in the company, valued at approximately $820,176.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CMO Stephany Verstraete sold 7,945 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $115,361.40. Following the transaction, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrew Turitz sold 6,190 shares of Teladoc Health stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the completion of the sale, the executive vice president now owns 39,429 shares in the company, valued at $572,509.08. The disclosure for this sale can be found here. Insiders sold a total of 135,441 shares of company stock worth $2,038,251 in the last 90 days. 1.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Lecap Asset Management Ltd. acquired a new stake in Teladoc Health during the fourth quarter valued at approximately $1,530,000. Sowell Financial Services LLC boosted its holdings in Teladoc Health by 40.8% in the fourth quarter. Sowell Financial Services LLC now owns 18,907 shares of the health services provider’s stock worth $407,000 after purchasing an additional 5,475 shares during the period. Deutsche Bank AG increased its stake in Teladoc Health by 12.4% during the third quarter. Deutsche Bank AG now owns 301,147 shares of the health services provider’s stock valued at $5,598,000 after purchasing an additional 33,287 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in shares of Teladoc Health during the third quarter worth $680,000. Finally, QRG Capital Management Inc. bought a new position in shares of Teladoc Health in the 3rd quarter worth about $392,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.